Results 41 to 50 of about 1,127,554 (354)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Radiotherapy Issues After Neoadjuvant Chemotherapy [PDF]

JNCI Monographs, 2015
Radiotherapy (RT) is standard following neoadjuvant chemotherapy (NCT) and breast-conserving surgery. NCT leads to pathologic down-staging, allowing some patients to undergo breast-conserving therapy (BCT) instead of mastectomy. BCT can also be considered in select stage III patients who respond well to NCT.
Kimberley S, Mak, Jay R, Harris
openaire   +2 more sources

Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine

Cancers, 2022
Simple Summary Despite the increased use of neoadjuvant chemotherapy in the early setting of breast cancer, there is a clinical need for predictive markers of response in daily practice.
F. Derouane, C. van Marcke, M. Berlière, A. Gerday, L. Fellah, I. Leconte, M. V. van Bockstal, C. Galant, C. Corbet, F. Duhoux   +9 more
semanticscholar   +1 more source

Neoadjuvant Chemotherapy Improves the Immunosuppressive Microenvironment of Bladder Cancer and Increases the Sensitivity to Immune Checkpoint Blockade

Journal of Immunology Research, 2022
Although tumor immune microenvironment plays an important role in antitumor therapy, few studies explored the gene signatures associated with the tumor immune microenvironment of bladder cancer after neoadjuvant chemotherapy.
Hao Luo, Gao-Lei Liu, Dan Jian, Dan-Dan Liang, Xue-Mei Li, Li Zhong, Bo Yang, Jun Jiang, Dong Wang, Meng-Xia Li, Wei-Hua Lan, Nan Dai   +11 more
doaj   +1 more source

Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities [PDF]

, 2017
© 2017 The Author(s). Anti-cancer therapies including chemotherapy aim to induce tumour cell death. Cell death introduces alterations in cell morphology and tissue micro-structures that cause measurable changes in tissue echogenicity.
A Ahmed, A Guimond, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, A Sadeghi-Naini, B Banihashemi, B Fisher, B Ganeshan, BS Garra, BS Pio, BT Hennessy, C-P Chou, D Sethi, DA Mankoff, EJ Feleppa, EJ Feleppa, F Tixier, FJ Esteva, FL Lizzi, FT D’Astous, G Berger, G Minckwitz von, GJ Czarnota, GJ Czarnota, GN Hortobagyi, H Haibo, H Tadayyon, H Tadayyon, H Tadayyon, HC Kim, HM Kuerer, II Wistuba, J Czernin, JB Nikas, JPB O’Connor, K Brindle, K Sikora, K Suzuki, KA Wear, KM Brindle, KN Ogston, L Sannachi, LX Yao, M Dowsett, M Vaidya, MF Insana, ML Oelze, ML Oelze, N Duric, O Falou, O Falou, QH Huang, R Tiling, RM Haralick, RM Vlad, RM Vlad, SH Giordano, SH Giordano, SJ Cleator, SM Scholl, T Cover, TJ Larkin, U McDermott, V Goh, V Guarneri, X Li, Y Labyed   +70 more
core   +2 more sources

Morbidity and Mortality of Patients Who Underwent Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiotherapy vs Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma

JAMA Surgery, 2021
Key Points Question Is there any difference in the safety of neoadjuvant chemoradiotherapy (nCRT) followed by minimally invasive esophagectomy (MIE) for locally advanced esophageal squamous cell carcinoma (ESCC) compared with that of neoadjuvant ...
Hao Wang, Han Tang, Yong Fang, L. Tan, Jun Yin, Yaxing Shen, Z. Zeng, Jiangyi Zhu, Yingyong Hou, M. Du, Jia Jiao, Hongjing Jiang, L. Gong, Zhigang Li, Jun Liu, D. Xie, Wenfeng Li, C. Lian, Qiang Zhao, Chun Chen, B. Zheng, Y. Liao, Kuo Li, Hecheng Li, Han-Yun Wu, L. Dai, Ke-Neng Chen   +26 more
semanticscholar   +1 more source

Noninvasive assessment of response to neoadjuvant chemotherapy in osteosarcoma of long bones with diffusion-weighted imaging: an initial in vivo study. [PDF]

PLoS ONE, 2013
OBJECTIVES: The purpose of our study is to investigate whether diffusion-weighted imaging (DWI) is useful for monitoring the therapeutic response after neoadjuvant chemotherapy in osteosarcoma of long bones.
Cheng-Sheng Wang, Lian-Jun Du, Ming-Jue Si, Qi-Hua Yin, Liang Chen, Min Shu, Fei Yuan, Xiao-Chun Fei, Xiao-Yi Ding   +8 more
doaj   +1 more source

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study [PDF]

, 2019
Background Eribulin mesylate (E) is indicated for metastatic breast cancer patients previously treated with anthracycline and taxane. We argued that E could also benefit patients eligible for neoadjuvant chemotherapy. Methods Patients with primary triple
Apolone G., Bianchi G. V., Cazzaniga M. E., Colombo M. P., Cosimo S. D., Crippa F., de Braud F., De Santis M. C., Folli S., Generali D., Gulino A., Mariani L., Moretti A., Nicola M. D., Paolini B., Scaperrotta G., Torri V., Tripodo C., Verde N. L.   +18 more
core   +2 more sources

Evaluation of the efficacy and surgical-related safety of neoadjuvant immunochemotherapy in advanced resectable none small cell lung cancer (NSCLC)

Frontiers in Oncology, 2023
BackgroundThe emergence of immune checkpoint inhibitors (ICIs) has brought about a paradigm shift in the treatment landscape of non-small cell lung cancer (NSCLC).
Qin Wang, Chen Qi, Jing Luo, Nan Xu, Mao-tian Xu, Yong Qiang, Chi Zhang, Yi Shen   +7 more
doaj   +1 more source

Bayesian network meta-analysis of efficacy and safety of neoadjuvant therapy for non-small-cell lung cancer

Therapeutic Advances in Medical Oncology, 2020
Objective: Neoadjuvant chemotherapy has increased the survival benefit of non-small cell lung cancer (NSCLC) patients. The effects of different neoadjuvant therapies are still controversial. We carried out the study to evaluate the efficacy and safety of
Yijiu Ren, Hai Tang, Jie Zhang, Yunlang She, Xiaoting Sun, Dong Xie, Chang Chen   +6 more
doaj   +1 more source